Skip to content
Peptigraph home
Shop Peptides50% off*

Kisspeptin-10 Benefits: Claims vs What Studies Show

Benefits people claim for Kisspeptin-10, set against what published studies measured, and where no study exists.

Medical review pendingGnRH stimulatorUpdated
Strongest evidence
Human RCT
Human / animal studies
14 / 4
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
research chemical

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Kisspeptin-10 claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
TestosteroneHuman RCT evidence, 4 of 43 / 0LH, FSH and testosterone (acute); Continuous 5-day infusion; Intermittent 12-day dosingEvidence for testosterone
Erectile dysfunctionHuman RCT evidence, 4 of 42 / 0Brain response to erotic stimuli; Limbic brain activity and moodNone
Liver healthAnimal evidence, 2 of 40 / 3Hepatic de novo lipogenesis; Hepatic steatosis; Liver antioxidant enzymesEvidence for liver health

Strongest study per claim: Testosterone, European journal of endocrinology 2026, PMID 42549827; Erectile dysfunction, JAMA network open 2022, PMID 36287566; Liver health, Cells 2025, PMID 40862768.

What the studies measured

Kisspeptin-10 outcomes in published studies
OutcomeResultStudy typeSource
LH, FSH and testosterone (acute)Acute kisspeptin-10 infusions raised LH, FSH and testosterone dose-dependently versus vehicle (P < .0001).Human RCTn = 15European journal of endocrinology 2026, PMID 42549827
Continuous 5-day infusionAfter 5 days of continuous infusion testosterone stayed elevated but gonadotropins matched vehicle.Human RCTn = 15European journal of endocrinology 2026, PMID 42549827
Intermittent 12-day dosingDaily 8-hour infusions over 12 days sustained gonadotropin increases.Human RCTn = 15European journal of endocrinology 2026, PMID 42549827
Ovulation after MVT-602Ovulation within 5 days: 100% (3 ug), 88% (1 ug), 82% (0.3 ug), 75% (0.1 ug) vs 60% on placebo.Human RCTFertility and sterility 2024, PMID 37925096
Brain response to erotic stimuliKisspeptin changed brain responses to erotic and attraction stimuli on fMRI; no symptom efficacy outcome in abstract.Human RCTn = 40JAMA network open 2022, PMID 36287566
Bone formation markerTotal osteocalcin rose a maximum of 20.3% after kisspeptin (P = .021).Human RCTn = 26The Journal of clinical endocrinology and metabolism 2022, PMID 35244717
Limbic brain activity and moodKisspeptin enhanced limbic brain activity in response to sexual and couple-bonding stimuli.Human RCTn = 29The Journal of clinical investigation 2017, PMID 28112678
Testosterone during infusionAt 4 ug/kg/h for 22.5 h, LH rose from 5.4 to 20.8 IU/liter and testosterone from 16.6 to 24.0 nmol/liter.Human controlled trialThe Journal of clinical endocrinology and metabolism 2011, PMID 21632807
Twice-weekly dosing for 8 weeksTwice-weekly KP-54 for 8 weeks kept reproductive hormones higher than saline.Human RCTClinical pharmacology and therapeutics 2010, PMID 20980998
Tachyphylaxis with repeated dosingLH and FSH responses fell sharply by day 14 of twice-daily injections (LH +2.5 IU/liter, FSH +0.5 IU/liter).Human RCTThe Journal of clinical endocrinology and metabolism 2009, PMID 19820030
LH by cycle phaseKisspeptin raised LH most in the preovulatory phase and least in the follicular phase.Human controlled trialThe Journal of clinical endocrinology and metabolism 2007, PMID 17635940
Egg maturation and pregnancyBiochemical pregnancy 40% (21/53); clinical pregnancy 23% (12/53).Human uncontrolled trialn = 53The Journal of clinical investigation 2014, PMID 25036713
Pulsatile LH restoredContinuous kisspeptin infusion restored gonadotropin pulsatility in patients with NKB-pathway mutations.Human uncontrolled trialNeuroendocrinology 2013, PMID 22377698
Sexual dimorphism of responseKisspeptin-10 raised gonadotropins in men and in preovulatory women but not in follicular-phase women.Human uncontrolled trialThe Journal of clinical endocrinology and metabolism 2011, PMID 21976724
Hepatic de novo lipogenesisKisspeptin reduced hepatic de novo lipogenesis of free fatty acids in steatotic mouse livers.Animal · mouse (not a human result)Cells 2025, PMID 40862768
Hepatic steatosisDeleting hepatic Kiss1r worsened steatosis; stimulating KISS1R protected against steatosis and reduced fibrosis in mice.Animal · mouse (not a human result)The Journal of clinical investigation 2022, PMID 35349482
Liver antioxidant enzymesKisspeptin raised liver SOD and catalase activity (p < 0.05) in rats.Animal · rat (not a human result)n = 24Cell biochemistry and function 2010, PMID 20517893
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND humans[mh]”: 110 results. PubMed search on 2 Oct 2026 for “(kisspeptin[tiab]) AND humans[mh] AND (randomized controlled trial[pt] OR clinical trial[pt])”: 54 results. PubMed search on 2 Oct 2026 for “kisspeptin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) AND humans[mh]”: 13 results. PubMed search on 2 Oct 2026 for “kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab])”: 90 results.

The testosterone claim: hormone rises in healthy men, tested with infusions

In healthy men, subcutaneous kisspeptin-10 infusions dose-dependently raised LH, FSH and testosterone against vehicle.[1]

After 5 days of continuous infusion the gonadotropin effect had faded, even though testosterone stayed elevated.[1]

An earlier study in men reported that boluses of kisspeptin-10 evoke LH secretion and that continuous infusion raised testosterone.[6]

The libido and mood claim: brain imaging, not symptom scores

In healthy men, kisspeptin versus vehicle enhanced limbic brain activity to sexual and couple-bonding images and lowered negative mood.[5]

In premenopausal women with hypoactive sexual desire disorder, a kisspeptin-54 infusion changed brain responses to erotic and face stimuli, and was reported well tolerated.[3]

The women's trial reports the result as laying a foundation for clinical applications, not as a proven improvement in desire.[3]

Liver, bone and fertility claims

The liver claim comes from young male rats given kisspeptin-10, where the authors say it may have antioxidant effects on liver tissue.[15]

In healthy men, kisspeptin raised the bone-formation marker osteocalcin, with a maximal increase of 20.3%.[4]

In women undergoing IVF, a single kisspeptin-54 injection induced egg maturation, a fertility use rather than a general wellness benefit.[10]

A PubMed search on 2 Oct 2026 for kisspeptin with liver, NAFLD or hepatic words returned 68 records; the only liver study cached here is the rat experiment.

Calculated from source web/src/data/evidence/kisspeptin.json searches; date 2026-10-02; query kisspeptin[tiab] AND (liver[tiab] OR NAFLD[tiab] OR hepatic[tiab]); count 68. Formula: count reported as recorded

More on Kisspeptin-10

DosageSide effectsResultsHow it works

Common questions

Is Kisspeptin-10 proven to work?

The strongest study we summarise for Kisspeptin-10 is human rct evidence, among 18 studies. A trial result is not an approval; see the legal status.

What does kisspeptin do?

It is described as stimulating gonadotropin-releasing hormone release, which raises LH and FSH.[6]

What is kisspeptin peptide used for?

In the cached human trials it was studied for reproductive hormone release, egg maturation and brain responses, not as an approved treatment.[7]

More on Kisspeptin-10

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
  2. 2Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
  3. 3Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
  4. 4Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.The Journal of clinical endocrinology and metabolism · 2022PMID 35244717Accessed 2 Oct 2026
  5. 5Kisspeptin modulates sexual and emotional brain processing in humans.The Journal of clinical investigation · 2017PMID 28112678Accessed 2 Oct 2026
  6. 6Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
  7. 7Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
  8. 8Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
  9. 9Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.The Journal of clinical endocrinology and metabolism · 2007PMID 17635940Accessed 2 Oct 2026
  10. 10Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.The Journal of clinical investigation · 2014PMID 25036713Accessed 2 Oct 2026
  11. 11Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications.Neuroendocrinology · 2013PMID 22377698Accessed 2 Oct 2026
  12. 12The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.The Journal of clinical endocrinology and metabolism · 2011PMID 21976724Accessed 2 Oct 2026
  13. 13Kisspeptin Mitigates Hepatic De Novo Lipogenesis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Cells · 2025PMID 40862768Accessed 2 Oct 2026
  14. 14Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model.The Journal of clinical investigation · 2022PMID 35349482Accessed 2 Oct 2026
  15. 15Direct and indirect effects of kisspeptin on liver oxidant and antioxidant systems in young male rats.Cell biochemistry and function · 2010PMID 20517893Accessed 2 Oct 2026
  16. 16PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND humans[mh] (110 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: (kisspeptin[tiab]) AND humans[mh] AND (randomized controlled trial[pt] OR clinical trial[pt]) (54 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: kisspeptin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) AND humans[mh] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: kisspeptin[tiab] AND (menopaus*[tiab] OR postmenopaus*[tiab]) (89 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: kisspeptin[tiab] AND (liver[tiab] OR NAFLD[tiab] OR hepatic[tiab]) (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin-54"[tiab] OR kisspeptin[tiab]) AND humans[mh] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  23. 23PubMed search: (kisspeptin[tiab]) AND (nausea[tiab] OR flush*[tiab] OR "injection site"[tiab] OR headache[tiab] OR "ovarian hyperstimulation"[tiab] OR tachyphylaxis[tiab] OR desensiti*[tiab]) AND humans[mh] (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  24. 24PubMed search: (kisspeptin[tiab] OR "kisspeptin-54"[tiab] OR "kisspeptin-10"[tiab]) AND ("clinical trial"[pt] OR "randomized controlled trial"[pt]) AND (women[tiab] OR men[tiab]) AND (adverse[tiab] OR tolerat*[tiab] OR "side effects"[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026

Found an error? Report a correction.